Compare Illumina, Inc. (ILMN) vs JPMorgan Ultra Short Income ETF (JPST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs JPMorgan Ultra Short Income ETF — how do they compare? Illumina, Inc. trades at $184.68 (market cap $27.94B), while JPMorgan Ultra Short Income ETF trades at $50.49. The key difference: Illumina, Inc. is trading nearer its 52-week high, JPMorgan Ultra Short Income ETF nearer its low. Which is the better fit depends on your goals.
| ILMN | JPST | |
|---|---|---|
Market Cap | $27.94B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $194.33 | $50.78 |
52-Week Low | $91.00 | $50.40 |
Enterprise Value | $29.33B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
JPST trades at $50.49, showing minimal daily movement with a slight decline of $0.01 (-0.02%). The technical outlook is bearish based on moving averages, while oscillators signal neutrality. Recent news highlights institutional interest, with Greenwood Gearhart LLC increasing its holdings by 9.6% as of July 2026. The ETF focuses on ultra-short income, offering a cash alternative with low duration risk, as noted in Seeking Alpha analysis from April 2026.
The outlook for JPST remains stable, appealing to risk-averse investors seeking capital preservation and modest income through dividends. Key risks include interest rate sensitivity and macroeconomic shifts affecting short-term bonds. Institutional accumulation supports confidence, but the bearish technical signal warrants caution for short-term traders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About JPMorgan Ultra Short Income ETF
JPST is an actively managed ETF that invests in short-term, investment-grade fixed income securities. It aims to provide current income and capital preservation while maintaining high liquidity.
Read more on JPST →
